Market Overview

Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer

Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer

Bioverativ Inc (NASDAQ: BIVV) agreed to be acquired by Sanofi SA (ADR) (NYSE: SNY) in an $11.6-billion all-cash deal, with the offer price valuing each of Bioverativ shares at $105. The offer price represents a 64-percent premium to Bioverativ's closing price prior to the deal announcement. 

The deal, announced Jan. 22, is expected to close within three months.

Bioverativ shares rose 64.40 percent on Jan. 22 in reaction to the news.

The Analyst

Argus analyst Jasper Hellweg downgraded the shares of Bioverativ from Buy to Hold.

The Thesis

Bioverativ shares are trading at 30.8 times Argus' 2018 earnings per share estimate, well above the 18.8 times, on average, for the peer group, including Biogen Inc (NASDAQ: BIIB), Celgene Corporation (NASDAQ: CELG) and Amgen, Inc. (NASDAQ: AMGN), Hellweg said in a Wednesday note. (See the analyst's track record here.) 

The shares have run up 85 percent since Argus's September upgrade, including the solid jump following the Sanofi offer, Hellweg said.

A Hold rating is now appropriate given the strong run-up and the forthcoming acquisition, according to Argus. Shares are fully valued at today's levels, the firm said. 

The Price Action

Bioverativ shares, which were up about 52 percent for the past year until the Sanofi deal announcement, were down 0.11 percent at the time of publication Wednesday morning. 

Related Links:

Pharma M&A Picks Up Momentum

What You Need to Know About Puma Biotech's 25% Slide

Latest Ratings for BIVV

Jan 2018MaintainsNeutralNeutral
Jan 2018DowngradesBuyHold
Jan 2018DowngradesBuyHold

View More Analyst Ratings for BIVV
View the Latest Analyst Ratings

Posted-In: ArgusAnalyst Color Biotech M&A News Downgrades Analyst Ratings General Best of Benzinga


Related Articles (AMGN + BIIB)

View Comments and Join the Discussion!

Latest Ratings

PNRJefferiesInitiates Coverage On
IPHIBank of AmericaMaintains80.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

A Contrarian Dividend Idea

Another Fed Shutdown Is More Likely Than Not In February, Says Height Securities